Pharmaceuticals

Allergan Plc on Thursday sued Pfizer Inc to require its rival to cover any damages it is forced to pay as a result of hundreds of lawsuits claiming Allergan deceptively marketed an opioid...

Durex, owned by Reckitt Benckiser, has recalled some batches of its “Real Feel” and “Latex Free” condoms in the United Kingdom and Ireland due to concerns they may burst. “Our tests have shown...

Nigeria has recalled 2.4 million bottles of cough syrup containing codeine after national outrage earlier this year over endemic use of opioids. Nigeria imposed a ban on the production and import of codeine...

Biogen Inc reported a better-than-expected quarterly profit on Tuesday and raised its forecast for 2018 adjusted earnings, driven by strong demand for its rare muscle disease treatment Spinraza, sending its shares up more...

Agios Pharmaceuticals Inc said on Friday the U.S. Food and Drug Administration approved its treatment for a type of leukemia, the first targeted drug for patients with a specific genetic mutation. The company...

Pfizer Inc said on Wednesday it would reorganize into three units, separating its consumer healthcare business that the U.S. drugmaker has been trying to sell since last year. The news comes a day...

AstraZeneca has won rapid regulatory approval for new uses of two of its important cancer drugs in Japan, less than six months after the first global approvals in Western markets. The decisions by...

Swiss pharmaceutical giant Novartis said Friday it planned to cut loose its Alcon eye care division, and aimed to buy back $5.0 billion of its own shares by the end of 2019. Novartis...

Puma Biotechnology Inc said on Tuesday a committee of the European Medicines Agency was likely to give positive opinion on its breast cancer drug, five months after the regulator recommended against approving it....

Swiss drugmaker Roche is paying $2.4 billion to buy the rest of Foundation Medicine (FMI), raising its bet on the U.S. genomic profiling group’s ability to personalize cancer care. The deal, backed by...